The combination of tools and know-how

To support innovative and strategic drug development.

Ask our experts

Our mission

JC Discovery® offers the combination of predictive preclinical models and innovative translational services that originate from its two founding entities, the Center of Immunophenomics (CIPHE; INSERM, CNRS, AMU) and Janvier Labs, both located in France.  

The unique JC Discovery® knowledge environment offers a comprehensive range of services permitting to develop in vitro and in vivo gene-edited preclinical models and to characterize the mouse, rat, and human immune systems using high-content immune-profiling.

At JC Discovery®, we support pharma and biotech strategic drug development in the field of immuno-oncology, inflammation, and auto-immune diseases

With academic connections, know-how, state-of-the-art technology platforms, and integrated data analysis, JC Discovery® also developed an innovative Fast-TrackTM pipeline based on primary human T-cells and omics, aiming at identifying, validating and prioritizing drug targets and at elucidating the mechanisms of action of new innovative immuno-therapeutics.

JC Discovery® & Innovation

With decades of academic expertise leading successful translational projects and partnering with major public institution teams and private pharmaceutical companies,  JC Discovery® has made innovation the corner-stone to advance new therapeutics from discovery, preclinical to move them efficiently to clinical stage of development.

JC Discovery® develops new translational approaches using primary human T-cells aiming at identifying, validating, and prioritizing drug targets and at elucidating the mechanisms of action of new innovative immunotherapeutic drugs.

Learn more

Our values

Scientific excellence

JC Discovery® is committed to scientific excellence, R&D expertise to bringing our customers the best chance of success to develop their innovative therapeutics.

High quality

With over 60 years' experience, our Team provides high added value to researchers to to give the best chance of success to their R&D programs.

Customer satisfaction

JC Discovery® is committed to delivering the highest level of client satisfaction from the initial phase of project strategy to the delivery of your models and research programs results.

The JC Discovery® team

JC Discovery® scientists have and extensive expertise in the discovery and pre-clinical validation of the efficacy and the mechanism of action of immune-related therapeutics. We are eager to share our scientific knowledge with academia, biotechs, pharma, and scientific organizations world-wide to stimulate and help innovative therapeutic developments. 

Thomas Janvier

Chief Executive Officer, Group

Thierry Jean

Chief Executive Officer MiMabs,
JC Discovery and Xentech

Bernard Malissen

Chief Scientific Officer, Group

François Romagné

Scientific Advisor

Ana Zarubica

Co-founder, Scientific Director and Operation Coordinator

Frédéric Fiore

Scientific Advisor, Fast-Track Design

Hervé Luche

Co-founder, Scientific Advisor, Fast-Track Immunomics

Anaïs Joachim

Study Director

Javier Celis Gutierrez

Study Director

Quentin Lecocq

Business Developer Immuno-Oncology, JC Discovery and MiMabs

JC Discovery® & Partners

JC Discovery® benefits from multiple connections with industrial and academic players like the Institute Curie. The network of academic research institutions partnering with JC Discovery® also includes the Center of Immunophenomics (CIPHE) and the Center of Immunology Marseille - Luminy (CIML). 

With Mérieux Equity Partners, the newly created Group, including JC Discovery® aims at creating a world leader in translational research, by pursuing the development of its offer of innovative research models with high added value services. This support allows to develop further innovation to bring solutions to the emergingcustomers needs of high value in vitro and in vivo models, together with early preclinical services.

By forging alliances with academic and industry partners, JC Discovery® stands on bold research to fulfill its mission:
advancing the development and understanding of the mechanism of action of breakthrough immune-related therapies.

Janvier Labs

An international company that is among the world leaders in the breeding of laboratory rodents and associated services.

See more


The Immunophenomique Center (CIPHE) is an advanced services platform of Inserm (US012), the CNRS (UMS3367) and Aix Marseille University (AMU).

See more


XenTech is a spin-off of Institut Curie, France’s largest cancer research institute. XenTech is a major partner in the evaluation of oncology drugs using PDX models.

See more


MImAbs is an R&D Platform for the generation and characterization of immunotherapy antibodies. By converting the most promising targets from academia, start-ups and industry into next generation immunotherapies against cancer and inflammatory diseases, keeping one step ahead of the competition.

See more

Merieux Equity Partner

Venture Capital and Growth/Buyout Private Equity Investment Firm focused on Healthcare and Nutrition.

See more


Founded in 1976, the Centre d’Immunologie de Marseille-Luminy is a research institute internationally renowned in its discipline which has developed an organization and practices designed to foster the creativity and risk-taking of its researchers.

See more

Institut Curie

Public foundation established in 1909 by Marie Curie, the Institut Curie is one of the largest cancer research centers in Europe and always at the forefront, “from basic research to innovative treatments”. The Institut Curie brings together 3,000 researchers, doctors, caregivers, technicians and administrators.

See more

Follow our news, webinars and publications

Join the team

Our team is recruiting

Sales position

Very short description here.

Dolorem Quia Fuga

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea